ArticleFrontiers of medicine2017
Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum.
Article in Frontiers of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Angel or devil: the dual roles of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside in the development of liver injury based on integrating pharmacological techniques: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Tetrahydroxy stilbene glucoside rejuvenates aging hematopoietic stem cells with predilection for lymphoid differentiation via AMPK and Tet2.Journal of advanced research · 2025Article
- Processing ofFrontiers in pharmacology · 2024Article
- Growing attention on the toxicity of Chinese herbal medicine: a bibliometric analysis from 2013 to 2022.Frontiers in pharmacology · 2024Article
- New Insights into Herb-Induced Liver Injury.Antioxidants & redox signaling · 2023Review
- Discovery of Hepatotoxic Equivalent Markers and Mechanism ofMolecules (Basel, Switzerland) · 2022Article
- Transformation of Stilbene Glucosides FromFrontiers in pharmacology · 2022Article
- Editorial: Application of plant secondary metabolites to pain neuromodulation, volume II.Frontiers in pharmacology · 2022Article
- Alismatis Rhizoma methanolic extract-Effects on metabolic syndrome and mechanisms of triterpenoids using a metabolomic and lipidomic approach.Frontiers in pharmacology · 2022Article
- Hepatic Organoid-Based High-Content Imaging Boosts Evaluation of Stereoisomerism-Dependent Hepatotoxicity of Stilbenes in Herbal Medicines.Frontiers in pharmacology · 2022Article
- Beware of the Potential Risks for Polygoni Multiflori Caulis-Induced Liver Injury.Frontiers in pharmacology · 2022Article
- Article
- High-Throughput Identification of Organic Compounds from Polygoni Multiflori Radix Praeparata (Molecules (Basel, Switzerland) · 2021Article
- Investigation of the idiosyncratic hepatotoxicity of Polygonum multiflorum Thunb. through metabolomics using GC-MS.BMC complementary medicine and therapies · 2021Article
- Herb-Induced Liver Injury Related toFrontiers in pharmacology · 2021Review
- Screening of Quality Markers During the Processing ofFrontiers in pharmacology · 2021Article
- Main Active Components and Cell Cycle Regulation Mechanism of Astragali Radix and Angelicae Sinensis Radix in the Treatment of Ox-LDL-Induced HUVECs Injury and Inhibition of Their Cell Cycle.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Susceptibility-Related Cytokine Panel for Prediction ofJournal of inflammation research · 2021Article
- NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity.Frontiers in cell and developmental biology · 2021Review
- 2,3,5,4'-Tetrahydroxy-stilbene-2-Pharmaceutical biology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main constituents of a typical medicinal herb, Polygonum multiflorum (Heshouwu in Chinese), that induces idiosyncratic liver injury remain unclear. Our previous work has shown that cotreatment with a nontoxic dose of lipopolysaccharide (LPS) and therapeutic dose of Heshouwu can induce liver injury in rats, whereas the solo treatment cannot induce observable injury. In the present work, using the constituent "knock-out" and "knock-in" strategy, we found that the ethyl acetate (EA) extract of Heshouwu displayed comparable idiosyncratic hepatotoxicity to the whole extract in LPS-treated rats. Results indicated a significant elevation of plasma alanine aminotransferase, aspartate aminotransferase, and liver histologic changes, whereas other separated fractions failed to induce liver injury. The mixture of EA extract with other separated fractions induced comparable idiosyncratic hepatotoxicity to the whole extract in LPS-treated rats. Chemical analysis further revealed that 2,3,5,4'-tetrahydroxy trans-stilbene-2-O-β-glucoside (trans-SG) and its cis-isomer were the two major compounds in EA extract. Furthermore, the isolated cis-, and not its trans-isomer, displayed comparable idiosyncratic hepatotoxicity to EA extract in LPS-treated rats. Higher contents of cis-SG were detected in Heshouwu liquor or preparations from actual liver intoxication patients associated with Heshouwu compared with general collected samples. In addition, plasma metabolomics analysis showed that cis-SG-disturbing enriched pathways remarkably differed from trans-SG ones in LPS-treated rats. All these results suggested that cis-SG was closely associated with the idiosyncratic hepatotoxicity of Heshouwu. Considering that the cis-trans isomerization of trans-SG was mediated by ultraviolet light or sunlight, our findings serve as reference for controlling photoisomerization in drug discovery and for the clinical use of Heshouwu and stilbene-related medications.
Indexed as
Identifiers
28315126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.